Does LENVATINIB Cause Myelosuppression? 176 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 176 reports of Myelosuppression have been filed in association with LENVATINIB (Lenvima). This represents 0.5% of all adverse event reports for LENVATINIB.
176
Reports of Myelosuppression with LENVATINIB
0.5%
of all LENVATINIB reports
8
Deaths
105
Hospitalizations
How Dangerous Is Myelosuppression From LENVATINIB?
Of the 176 reports, 8 (4.5%) resulted in death, 105 (59.7%) required hospitalization, and 7 (4.0%) were considered life-threatening.
Is Myelosuppression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LENVATINIB. However, 176 reports have been filed with the FAERS database.
What Other Side Effects Does LENVATINIB Cause?
Diarrhoea (4,262)
Hypertension (4,152)
Fatigue (3,603)
Decreased appetite (3,257)
Malignant neoplasm progression (2,929)
Nausea (2,492)
Blood pressure increased (2,228)
Vomiting (1,962)
Asthenia (1,643)
Malaise (1,602)
What Other Drugs Cause Myelosuppression?
CYCLOPHOSPHAMIDE (3,603)
CARBOPLATIN (2,624)
TRASTUZUMAB (2,552)
PACLITAXEL (2,522)
TISLELIZUMAB (2,142)
CYTARABINE (1,869)
VENETOCLAX (1,864)
CISPLATIN (1,849)
BEVACIZUMAB (1,744)
SODIUM (1,696)
Which LENVATINIB Alternatives Have Lower Myelosuppression Risk?
LENVATINIB vs LEPONEX
LENVATINIB vs LERCANIDIPINE
LENVATINIB vs LETAIRIS
LENVATINIB vs LETERMOVIR
LENVATINIB vs LETROZOLE